These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6127353)

  • 21. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiological aspects of tardive dyskinesia.
    Kane JM; Woerner M; Lieberman J
    Encephale; 1988 Sep; 14 Spec No():191-4. PubMed ID: 3063513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidemiology of tardive dyskinesias in the Maghreb].
    Moussaoui D; Douki S; Bentounsi B; Otarid A; Chorfi M; Mamou A; Benamor L
    Encephale; 1988 Sep; 14 Spec No():203-8. PubMed ID: 2905647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of tardive dyskinesia in fluphenazine-treated patients.
    Yassa R; Iskandar H; Ally J
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):17S-20S. PubMed ID: 3220966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.
    van Os J; Walsh E; van Horn E; Tattan T; Bale R; Thompson SG
    Acta Psychiatr Scand; 2000 Apr; 101(4):300-6. PubMed ID: 10782550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
    Harris MJ; Panton D; Caligiuri MP; Krull AJ; Tran-Johnson TK; Jeste DV
    Psychopharmacol Bull; 1992; 28(1):87-92. PubMed ID: 1609047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results.
    Kalachnik JE; Harder SR; Kidd-Nielsen P; Errickson E; Doebler M; Sprague RL
    Psychopharmacol Bull; 1984; 20(1):27-32. PubMed ID: 6144132
    [No Abstract]   [Full Text] [Related]  

  • 30. Tardive dyskinesia: determinants of temporal dynamics of its emergence.
    Latalova K
    Neuro Endocrinol Lett; 2008 Dec; 29(6):995-8. PubMed ID: 19112392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal involuntary movements in patients on long-acting neuroleptics.
    Oyewumi LK; Lapierre YD; Gray R; Batth S; Gelfand R
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):719-23. PubMed ID: 6141614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does clozapine cause tardive dyskinesia?
    Kane JM; Woerner MG; Pollack S; Safferman AZ; Lieberman JA
    J Clin Psychiatry; 1993 Sep; 54(9):327-30. PubMed ID: 8104929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of spontaneous dyskinesia in schizophrenia.
    Fenton WS
    J Clin Psychiatry; 2000; 61 Suppl 4():10-4. PubMed ID: 10739325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The problem of tardive akathisia.
    Gualtieri CT
    Brain Cogn; 1993 Sep; 23(1):102-9. PubMed ID: 8105819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognosis of tardive dyskinesia.
    Gardos G; Cole JO
    J Clin Psychiatry; 1983 May; 44(5):177-9. PubMed ID: 6133847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.